Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey.
PTA CONNECTED INITIATIVE HELPS FAMILIES NAVIGATE RAISING CHILDREN IN THE DIGITAL AGE; PROVIDES FREE TOOLS TO HELP SET HEALTHY LIMITS AND CREATE POSITIVE EXPERIENCES
ALEXANDRIA,...
Despite nearly all professional caregivers agreeing that informal caregivers can help bridge the demand of caregiving in Singapore to a certain extent (30% large,...
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company’s common stock to institutional or accredited investors.
NEWARK, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- HealthSure 3X, an online health solutions company headquartered in New Jersey, has introduced a fully integrated platform where patients can avail themselves of licensed healthcare professionals at home using virtual in-home medical care. This method caters to growing needs for accessible and flexible healthcare while upholding professional standards and patient safety.
AI technology boosts face-to-face time with patients, earns Mercy national recognition for physician satisfaction
ST. LOUIS, July 23, 2025 /PRNewswire/ -- Mercy's strategic and carefully planned...
New Funding Opportunity Seeks Catalytic Solutions to Address Data Demand
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Cambiar Education, with support from the Walton Family...
Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence
CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech...
New York City, NY, July 21, 2025 (GLOBE NEWSWIRE) -- PhenQ is leading the 2025 weight loss revolution with a science-backed natural appetite suppressant—no needles, no harsh side effects, just sustainable, healthy weight control
GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in...
REXBURG, Idaho, July 18, 2025 /PRNewswire/ -- Activated Insights, the leading provider of experience management and training solutions for long-term and post-acute care organizations,...
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –